

CytomX Therapeutics, Inc.  
Form 8-K  
January 29, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 24, 2018**

**CYTOMX THERAPEUTICS, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-37587**  
**(Commission File Number)**

**27-3521219**  
**(IRS Employer**

**151 Oyster Point Blvd.**

**Suite 400**

**Identification No.)**

Edgar Filing: CytomX Therapeutics, Inc. - Form 8-K

**South San Francisco, CA 94080**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (650) 515-3185**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**
*Compensatory Arrangements of Certain Officers*

On January 24, 2018, the Compensation Committee of the Board of Directors (the Board) of CytomX Therapeutics, Inc. (the Company) approved: (a) annual base salaries for 2018 and (b) cash performance bonuses for 2017 for the following principal financial officer and named executive officers of the Company:

<b>Name and Current Position</b>	<b>Salary Increase (%)</b>	<b>Salary Increase (\$)</b>	<b>2018 Base Salary</b>	<b>2017 Cash Bonus</b>
Debanjan Ray, Chief Financial Officer and Head of Corporate Development	5.0%	\$ 18,750	\$ 393,750	\$ 228,750
Rachel W. Humphrey, M.D., Chief Medical Officer	7.2%	\$ 29,638	\$ 440,448	\$ 244,426
W. Michael Kavanaugh, M.D., Chief Scientific Officer and Head of Research and Non-Clinical Development	4.0%	\$ 16,436	\$ 427,357	\$ 201,351

On January 24, 2018, the Board approved the annual base salary for 2018 and cash performance bonus for 2017 for the following principal executive officer:

<b>Name and Current Position</b>	<b>Salary Increase (%)</b>	<b>Salary Increase (\$)</b>	<b>2018 Base Salary</b>	<b>2017 Cash Bonus</b>
Sean A. McCarthy, D. Phil., President and Chief Executive Officer	10.0%	\$ 50,000	\$ 550,000	\$ 425,000

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 29, 2018

**CYTOMX THERAPEUTICS, INC.**

By: /s/ Debanjan Ray  
Debanjan Ray  
Chief Financial Officer